Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 9/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | BTK | Q06187 | 2/20 | 0.50 |
| ▸ | CHUK | O15111 | 3/20 | 0.47 |
| ▸ | CDC7 | O00311 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | LIMK1 | P53667 | 5/20 | 0.38 |
| ▸ | PRKACA | P17612 | 2/20 | 0.38 |
| ▸ | EEF2K | O00418 | 1/20 | 0.38 |
| ▸ | PLK4 | O00444 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6194644 | 0.85 | IKBKB (0.50) | IKBKBCYP1A2CYP2C9CYP3A4BTK | |
| SCHEMBL614111 | 0.83 | GSK3B (0.42) | IKBKBCYP1A2CYP2C9CYP3A4BTK | |
| SCHEMBL15960083 | 0.81 | MAPT (0.51) | IKBKBCYP1A2CYP2C9CYP3A4BTK | |
| Lithium Ion SCHEMBL30334419 | 0.79 | GSK3B (0.40) | IKBKBCYP1A2CYP2C9CYP3A4BTK | |
| SCHEMBL16246374 | 0.78 | GSK3B (0.42) | IKBKBCYP1A2CYP2C9CYP3A4BTK | |
| SCHEMBL23997366 | 0.77 | GSK3B (0.44) | IKBKBCYP1A2CYP2C9CYP3A4BTK | |
| SCHEMBL25482100 | 0.77 | GSK3B (0.41) | IKBKBCYP1A2CYP2C9CYP3A4BTK | |
| SCHEMBL102283 | 0.76 | KDM4E (0.53) | IKBKBCYP1A2CYP2C9CYP2C19MAPT | |
| SCHEMBL15943484 | 0.74 | IKBKB (0.50) | IKBKBCYP1A2CYP2C9CYP3A4BTK | |
| SCHEMBL12247521 | 0.74 | IKBKB (0.56) | IKBKBCYP1A2CYP2C9CYP3A4BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3533797-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-12-20 | — | — | EP | disclosed |
| CN-112409373-A | Substituted [5,6] cyclo-4 (3H) -pyrimidinones as anticancer agents | 南京正济医药研究有限公司 | 2021-02-26 | — | — | CN | disclosed |
| CN-110381950-B | Substituted [5,6] cyclo-4 (3H) -pyrimidinones as anticancer agents | 南京正济医药研究有限公司 | 2020-09-04 | — | — | CN | disclosed |
| US-10745410-B2 | Substituted [5,6]cyclic-4(3H)-pyrimidinones as anticancer agents | ZENJI RESEARCH LABORATORIES (CN) | 2020-08-18 | — | — | US | disclosed |
| US-10745410-B2 | Substituted [5,6]cyclic-4(3H)-pyrimidinones as anticancer agents | ZENJI RESEARCH LABORATORIES (CN) | 2020-08-18 | — | — | US | disclosed |
| US-20200055867-A1 | SUBSTITUTED [5,6]CYCLIC-4(3H)-PYRIMIDINONES AS ANTICANCER AGENTS | ZENJI RESEARCH LABORATORIES (CN) | 2020-02-20 | — | — | US | disclosed |
| US-20200055867-A1 | SUBSTITUTED [5,6]CYCLIC-4(3H)-PYRIMIDINONES AS ANTICANCER AGENTS | ZENJI RESEARCH LABORATORIES (CN) | 2020-02-20 | — | — | US | disclosed |
| CN-110381950-A | Substituted [5,6] cyclo-4 (3H) -pyrimidinones as anticancer agents | 南京正济医药研究有限公司 | 2019-10-25 | — | — | CN | disclosed |
| EP-3533797-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-09-04 | — | — | EP | disclosed |
| EP-2540728-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-04-10 | — | — | EP | disclosed |
| US-20060058522-A1 | Thiophene-carboxamide derivatives and their use as inhibitors of the enzyme ikk-2 | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
| CN-1738812-A | Thiophenecarboxamides as inhibitors of the enzyme IKK-2 | ASTRAZENECA AB (SE) | 2006-02-22 | — | — | CN | disclosed |
| EP-1583756-A1 | THIOPHENE CARBOXAMIDES AS INHIBITORS OF THE ENZYME IKK-2 | AstraZeneca AB (SE) | 2005-10-12 | — | — | EP | disclosed |
| EP-1583755-A1 | THIOPHENE-CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZIME IKK-2 | AstraZeneca AB (SE) | 2005-10-12 | — | — | EP | disclosed |
| US-20040235821-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-11-25 | — | — | US | disclosed |
| CN-1538968-A | Novel compounds | — | 2004-10-20 | — | — | CN | disclosed |
| WO-2004063186-A1 | THIOPHENE-CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZIME IKK-2 | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | WO | disclosed |
| WO-2004063185-A1 | THIOPHENE CARBOXAMIDES AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | WO | disclosed |
| EP-1421079-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003010163-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058522-A1 | Thiophene-carboxamide derivatives and their use as inhibitors of the enzyme ikk-2 | NFKBIA, RELA, IKBKE | IKBKB 5/4885CYP1A2 355/4885CYP2C9 677/4885 |
| US-20200055867-A1 | SUBSTITUTED [5,6]CYCLIC-4(3H)-PYRIMIDINONES AS ANTICANCER AGENTS | CDC7, CDK7, CDK17 | IKBKB 1055/4885CYP1A2 3810/4885CYP2C9 3703/4885 |
| US-10745410-B2 | Substituted [5,6]cyclic-4(3H)-pyrimidinones as anticancer agents | CDC7, CDK7, CDK17 | IKBKB 1055/4885CYP1A2 3810/4885CYP2C9 3703/4885 |
| US-20040235821-A1 | Novel compounds | ABCG2, UGT1A1, SULT1E1 | IKBKB 2823/4885CYP1A2 8/4885CYP2C9 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.